Analyst Price Target is GBX 231
▲ +204.16% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for ANGLE in the last 3 months. The average price target is GBX 231, with a high forecast of GBX 231 and a low forecast of GBX 231. The average price target represents a 204.16% upside from the last price of GBX 75.95.
Current Consensus is
The current consensus among 1 contributing investment analysts is to buy stock in ANGLE.
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD multiplex analysis system for routine and focused multiplex analysis of DNA, RNA or protein biomarkers. The company was founded in 1994 and is based in Guildford, the United Kingdom.